Neuberger Berman Group
CRNX icon

Neuberger Berman Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Neuberger Berman Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Sell
7,038
-175,150
-96% -$7.82M ﹤0.01% 1904
2025
Q4 		$8.48M Buy
182,188
+115,040
+171% +$5.12M 0.01% 844
2025
Q3 		$2.8M Buy
+67,148
New +$2.15M ﹤0.01% 1087

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Neuberger Berman Group's CRNX Position: Q1 2026 in Review

Neuberger Berman Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 96% in Q1 2026, selling an estimated $7.82M and leaving 7,038 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #1904.

Neuberger Berman Group first reported a position in CRNX in Q3 2025 and has held it in 3 quarters since. The position peaked at $8.48M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Neuberger Berman Group held 7,038 shares of Crinetics Pharmaceuticals worth $256K as of Q1 2026.
  • Neuberger Berman Group sold 175,150 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $7.82M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1904 holding.
  • Neuberger Berman Group first reported a position in Crinetics Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Neuberger Berman Group's Crinetics Pharmaceuticals position peaked at $8.48M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.